Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults
Phase 2
Completed
- Conditions
- COVID-19, SARS CoV 2 Infection
- Interventions
- Biological: Pfizer/BNT vaccine (30 mcg)Biological: ChulaCov19 BNA159 vaccine (50 mcg)Biological: COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Technovalia, Pty Ltd
- Target Recruit Count
- 150
- Registration Number
- NCT05605470
- Locations
- 🇦🇺
Paratus research Canberra Clinic, Bruce, Australian Capital Territory, Australia
🇦🇺Paratus Clinical Research Western Sydney, Blacktown, New South Wales, Australia
🇦🇺The Children's Hospital at Westmead Sydney, Westmead, New South Wales, Australia
© Copyright 2025. All Rights Reserved by MedPath